Home > Insider Trading > Filing (0001209191-16-137674)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1383242	S James Scibetta	C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054	President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-08-15	9,123	$1.61	36,207	No	4	M	Direct
Common Stock	Acquisiton	2016-08-15	15,877	$1.61	52,084	No	4	M	Direct
Common Stock	Disposition	2016-08-15	25,000	$45.21	27,084	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2016-08-15	9,123	$0.00	9,123	$1.61
Common Stock	Stock Option (Right to Buy)	Disposition	2016-08-15	15,877	$0.00	15,877	$1.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-09-02	No	4	M	Direct
22,373		2020-09-02	No	4	M	Direct

Footnotes

The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.82 to$45.76, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth inthis footnote 2.
The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering.
The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.